CytoSorbents Q1 product rev $8.7M (-3%); FDA denies DrugSorb-ATR De Novo

Cytosorbents Corp

2025-Q1 EPS reported -$0.02 revenue$8,727,238

Product revenue $8.7M, flat constant currency vs Q1 2024 $9.0M; gross margin 71% vs 77%.
Net loss improved to $1.5M ($0.02/shr) from $6.1M; adjusted net loss $3.7M ($0.06/shr).
FDA denied DrugSorb-ATR De Novo on Apr 25, 2025; company plans formal appeal for 2025 decision.
Rights offering raised $6.8M net; cash & restricted cash $13.1M at Mar 31 vs $9.8M Dec 31.
Germany sales disruption offset by E.U. distributor growth; opened Dubai subsidiary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.